Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-07-18
2011-11-01
Berch, Mark (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S363000, C540S364000
Reexamination Certificate
active
08048874
ABSTRACT:
Substituted 2-(azetidin-2-on-1-yl)alkoxyalkylalkanoic acids and 2-(azetidin-2-on-1-yl)arylalkylalkanoic acids, and analogs and derivatives thereof are described. Methods for using the described compounds, and pharmaceutical compositions thereof, to treat disease states responsive to antagonism of one or more vasopressin receptors are also described.
REFERENCES:
patent: 3912743 (1975-10-01), Christensen et al.
patent: 4007196 (1977-02-01), Christensen et al.
patent: 4085225 (1978-04-01), Welle et al.
patent: 4136193 (1979-01-01), Bogese et al.
patent: 4314081 (1982-02-01), Molloy et al.
patent: 4341698 (1982-07-01), Carr et al.
patent: 4352752 (1982-10-01), Ojima et al.
patent: 4478836 (1984-10-01), Mouzin et al.
patent: 4536518 (1985-08-01), Welch
patent: 4576753 (1986-03-01), Kamiya et al.
patent: 4734498 (1988-03-01), Cooper et al.
patent: 4751299 (1988-06-01), Sugawara et al.
patent: 4761501 (1988-08-01), Husbands et al.
patent: 4772694 (1988-09-01), Cooper et al.
patent: 4956388 (1990-09-01), Robertson et al.
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5023252 (1991-06-01), Hseih
patent: 5759865 (1998-06-01), Bruns et al.
patent: 6204260 (2001-03-01), Bruns, Jr. et al.
patent: 6403632 (2002-06-01), Duan et al.
patent: 6610680 (2003-08-01), Bruns et al.
patent: 6627625 (2003-09-01), Koppel
patent: 7119083 (2006-10-01), Bruns, Jr. et al.
patent: 7179907 (2007-02-01), Eaton et al.
patent: 7268125 (2007-09-01), Bruns, Jr. et al.
patent: 2004/0132714 (2004-07-01), Zhou et al.
patent: 2005/0059650 (2005-03-01), Jones et al.
patent: 2006/0281728 (2006-12-01), Guillon et al.
patent: 2009/0170825 (2009-07-01), Koppel et al.
patent: 2010/0016274 (2010-01-01), Koppel et al.
patent: 0144840 (1985-06-01), None
patent: 0591040 (1993-09-01), None
patent: 56125361 (1981-10-01), None
patent: WO93/16609 (1993-06-01), None
patent: WO94/01402 (1994-01-01), None
patent: WO94/04494 (1994-03-01), None
patent: WO94/26735 (1994-11-01), None
patent: WO 97/30707 (1997-08-01), None
patent: WO 02/12187 (2002-02-01), None
patent: WO03/031407 (2003-04-01), None
patent: WO2006/102283 (2006-09-01), None
Jarrahpour, Molbank 2005, M439 (Oct. 1, 2005).
Jarrahpour, Molecules 2004, 9, 939-948.
Ojima, Journal of the American Chemical Society (1990), 112(2), 770-4.
Ojima, Journal of the American Chemical Society (1987), 109(21), 6537-8.
PCT International Search Report for PCT/US06/10192 completed by the U. S. Searching Authority (Jul. 1, 2008).
Serradeil-LeGal, et al., Biochemical and Pharmacological Properties of SR 49059, Journal of Clinical Investigation, 1993, vol. 92, 224-231.
International Search Report for PCT/US2006/027703 dated Mar. 30, 2007.
Hirai, Koichi, et al., “An Example of the B-Lactam Ring Rormation and Novel Pyrrolinoazetidinone Ring Construction”, 1985, Sankyo Kenkyusho Nempo, vol. 37. pp. 133-139.
Ojima, Iwao, et al., “Novel and Effective Routes to Optically Pure Amino Acids, Dipeptides, and Their Derivatives Via B-Lactams Obtained Through Asymmetric Cycloaddition”, 1987, Journal Chem. Soc. , Chem. Comm., pp. 625-626.
Ragner Liedman et al., “Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrheal”, Acta Obstetricia et Gynecologica. 85: 207-211, (2005).
R. Brouard et al., “Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea”, British Journal of Obstetrics and Gynecology, May 2000, vol. 107, pp. 614-619.
Hakimelahi, “The Synthesis of Highly Strained Monocyclic and Bicyclic Beta-Lactams (delta-Carbapenem),” Helvetica Chimica Acta, 1982, 65 Fasc., pp. 1378-1384.
Koppel Gary A.
Miller Marvin J.
Azevan Pharmaceuticals, Inc.
Barnes & Thornburg LLP
Berch Mark
LandOfFree
Beta-lactamyl phenylalanine, cysteine, and serine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Beta-lactamyl phenylalanine, cysteine, and serine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Beta-lactamyl phenylalanine, cysteine, and serine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4254429